S&P Futures
3,789.00 -0.50 (-0.01%) Dow Futures
30,757.00 -24.00 (-0.08%) Nasdaq Futures
11,540.00 +10.50 (+0.09%) Russell 2000 Futures
1,703.80 -4.20 (-0.25%) Crude Oil
106.15 +0.39 (+0.37%) Gold
1,807.60 +0.30 (+0.02%)
Inovio Pharmaceuticals, Inc. (INO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7900 |
| Open | 1.7400 |
| Bid | 1.7300 x 28000 |
| Ask | 1.7500 x 38800 |
| Day's Range | 1.6800 - 1.8400 |
| 52 Week Range | 1.3800 - 9.9600 |
| Volume | |
| Avg. Volume | 6,255,733 |
| Market Cap | 363.968M |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.67 |
- Motley Fool
Why Inovio Pharmaceuticals Stock Topped the Market on Monday
Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Previous to that, he worked in various positions at U.K. pharmaceutical company Shire in a stint that lasted roughly six years, and also held positions at Novartis and Novo Nordisk.
- PR Newswire
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovig
- InvestorPlace
7 Monkeypox Stocks That May Take Off in Q2
Once a problem confined to just one continent, Monkeypox is spreading and threatens to become a global issue. Since the United Kingdom first reported a confirmed Monkeypox case on May 7, many more cases have been reported in countries where the virus hasn’t been originally known to be present. Nearly 800 cases have been detected so far, and investors are rightfully researching Monkeypox stocks to buy to position themselves for a potential upside during the second quarter of 2022. According to th
